Other News To Note
Curetis AG, of Holzgerlingen, Germany, and Cempra Inc., of Chapel Hill, N.C., signed a research and development collaboration to incorporate Curetis' molecular diagnostic system into Cempra's global Phase III trial of oral solithromycin in community-acquired bacterial pneumonia. The randomized, double-blind Phase III trial comparing solithromycin against a comparator drug is expected to begin in the fourth quarter.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter